In a recent article on TCTMD, the author notes that the introduction of robotic systems into the cath lab, accompanied by their integration with other technologies, is expected to benefit both patients and physicians, as presented during a session devoted to innovation at TCT 2015. The piece notes that while the initial clinical trial to gain FDA 510(k) clearance for the CorPath System focused mainly on simple lesions, the system is currently being used in practice for more complex PCI procedures including bifurcation lesions, total occlusions, and high-risk PCI requiring support with the Impella® system.